Identification of a DNA methylation signature in blood cells from persons with down syndrome

Aging

Volumn 7, Issue 2, 2015, Pages 82-96

  Bacalini, Maria Giulia ^a,b   Gentilini, Davide ^c   Boattini, Alessio ^a   Giampieri, Enrico ^a   Pirazzini, Chiara ^a   Giuliani, Cristina ^a   Fontanesi, Elisa ^a   Scurti, Maria ^a   Remondini, Daniel ^a   Capri, Miriam ^a   Cocchi, Guido ^a   Ghezzo, Alessandro ^a   Rio, Alberto Del ^a,d   Luiselli, Donata ^a   Vitale, Giovanni ^c,e   Mari, Daniela ^e,f   Castellani, Gastone ^a   Fraga, Mario ^g,h   Di Blasio, Anna Maria ^c   Salvioli, Stefano ^a   Franceschi, Claudio ^a,i   Garagnani, Paolo ^a,b,j   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Personal Genomics Srl   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^h CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

ⁱ IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Aging; DNA methylation; Down syndrome; Epigenetics; Infinium human methylation 450 beadchip

Indexed keywords

DNA METHYLATION; DOWN SYNDROME; FEMALE; GENE ONTOLOGY; GENETIC EPIGENESIS; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MALE; METABOLISM;

DNA METHYLATION; DOWN SYNDROME; EPIGENESIS, GENETIC; FEMALE; GENE ONTOLOGY; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE;

EID: 84924940199     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100715     Document Type: Article

References (64)

1. Lejeune J, Gautier M, Turpin R. [Study of somatic chromosomes from 9 mongoloid children]. Comptes Rendus Hebd Séances Académie Sci. 1959; 248:1721-1722.
2. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A, National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birt Defects Res A Clin Mol Teratol. 2010; 88:1008-1016.
3. Roizen NJ, Patterson D. Down's syndrome. The Lancet. 2003 [cited 2013 July 11]; 361:1281-1289.
4. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002; 359:1019-1025.
5. Martin GM. Syndromes of accelerated aging. Natl Cancer Inst Monogr. 1982; 60:241-247.
6. Patterson D, Cabelof DC. Down syndrome as a model of DNA polymerase beta haploinsufficiency and accelerated aging. Mech Ageing Dev. 2012; 133:133-137.
7. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med. 1998; 25:1044-1048.
8. Nakamura E, Tanaka S. Biological ages of adult men and women with Down's syndrome and its changes with aging. Mech Ageing Dev. 1998; 105:89-103.
9. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun. 1998; 243:849-851.
10. Praticò D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, Violi F. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol. 2000; 48:795-798.
11. Zigman WB. Atypical aging in down syndrome. Dev Disabil Res Rev. 2013; 18:51-67.
12. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging. 2005; 26:383-389.
13. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet. 2006; 36:405-415.
14. Ghezzo A, Salvioli S, Solimando MC, Palmieri A, Chiostergi C, Scurti M, Lomartire L, Bedetti F, Cocchi G, Follo D, Pipitone E, Rovatti P, Zamberletti J, et al. Age-related changes of adaptive and neuropsychological features in persons with down syndrome. PloS One. 2014; 9:e113111.
15. Cossarizza A, Monti D, Montagnani G, Ortolani C, Masi M, Zannotti M, Franceschi C. Precocious aging of the immune system in Down syndrome: alteration of B lymphocytes, T-lymphocyte subsets, and cells with natural killer markers. Am J Med Genet Suppl. 1990; 7:213-218.
16. Cuadrado E, Barrena MJ. Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol. 1996; 78:209-214.
17. Cossarizza A, Ortolani C, Forti E, Montagnani G, Paganelli R, Zannotti M, Marini M, Monti D, Franceschi C. Age-related expansion of functionally inefficient cells with markers of natural killer activity in Down's syndrome. Blood. 1991; 77:1263-1270.
18. Roat E, Prada N, Lugli E, Nasi M, Ferraresi R, Troiano L, Giovenzana C, Pinti M, Biagioni O, Mariotti M, Di Iorio A, Consolo U, Balli F, et al. Homeostatic cytokines and expansion of regulatory T cells accompany thymic impairment in children with Down syndrome. Rejuvenation Res. 2008; 11:573-583.
19. Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr. 2012; 171:1301-1307.
20. Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome. Crit Rev Oncog. 2011; 16:25-36.
21. Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood. 2013; 122:e33-43.
22. Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Pérez-Jurado LA, Lehrach H, Herwig R. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics. 2011; 12:229.
23. Eckmann-Scholz C, Bens S, Kolarova J, Schneppenheim S, Caliebe A, Heidemann S, von Kaisenberg C, Kautza M, Jonat W, Siebert R, Ammerpohl O. DNA-Methylation Profiling of Fetal Tissues Reveals Marked Epigenetic Differences between Chorionic and Amniotic Samples. PLoS ONE. 2012 [cited 2013 July 11]; 7:e39014.
24. Jin S, Lee YK, Lim YC, Zheng Z, Lin XM, Ng DPY, Holbrook JD, Law HY, Kwek KYC, Yeo GSH, Ding C. Global DNA Hypermethylation in Down Syndrome Placenta. PLoS Genet [Internet]. 2013 [cited 2013 July 11]; 9. Available from: http://dx.doi.org/10.1371/journal.pgen.1003515
25. Kerkel K, Schupf N, Hatta K, Pang D, Salas M, Kratz A, Minden M, Murty V, Zigman WB, Mayeux RP, Jenkins EC, Torkamani A, Schork NJ, et al. Altered DNA methylation in leukocytes with trisomy 21. PLoS Genet. 2010; 6.
26. Jones MJ, Farré P, McEwen LM, Macisaac JL, Watt K, Neumann SM, Emberly E, Cynader MS, Virji-Babul N, Kobor MS. Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in Down syndrome. BMC Med Genomics. 2013; 6:58.
27. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009; 41:178-186.
28. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, Fan J-B, Shen R. High density DNA methylation array with single CpG site resolution. Genomics. 2011; 98:288-295.
29. Kusters MAA, Verstegen RHJ, Gemen EFA, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009; 156:189-193.
30. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012; 13:86.
31. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M, Shchetynsky K, Scheynius A, Kere J, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013; 31:142-147.
32. Du P, Zhang X, Huang C-C, Jafari N, Kibbe WA, Hou L, Lin SM. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics. 2010; 11:587.
33. Lam K, Zhang D-E. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci J Virtual Libr. 2012; 17:1120-1139.
34. Nižetić D, Groet J. Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer. 2012; 12:721-732.
35. Wang SS, Betz AG, Reed RR. Cloning of a novel Olf-1/EBF-like gene, O/E-4, by degenerate oligo-based direct selection. Mol Cell Neurosci. 2002; 20:404-414.
36. De Hingh YCM, van der Vossen PW, Gemen EFA, Mulder AB, Hop WCJ, Brus F, de Vries E. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr. 2005; 147:744-747.
37. Soshnikova N, Duboule D. Epigenetic regulation of vertebrate Hox genes: a dynamic equilibrium. Epigenetics Off J DNA Methylation Soc. 2009; 4:537-540.
38. Long HK, Blackledge NP, Klose RJ. ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem Soc Trans. 2013; 41:727-740.
39. He J, Shen L, Wan M, Taranova O, Wu H, Zhang Y. Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes. Nat Cell Biol. 2013; 15:373-384.
40. Wu X, Johansen JV, Helin K. Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. Mol Cell. 2013; 49:1134-1146.
41. Demirtas H. AgNOR status in Down's syndrome infants and a plausible phenotype formation hypothesis. Micron Oxf Engl 1993. 2009; 40:511-518.
42. Demirtas H, Imamoglu N, Dönmez H, Cücer N, Yilmaz A, Candemir Z. Condensed chromatin surface and NORs surface enhancement in mitogen-stimulated lymphocytes of Down syndrome patients. Ann Génétique. 2001; 44:77-82.
43. Briggs JA, Mason EA, Ovchinnikov DA, Wells CA, Wolvetang EJ. Concise review: new paradigms for Down syndrome research using induced pluripotent stem cells: tackling complex human genetic disease. Stem Cells Transl Med. 2013; 2:175-184.
44. Chou ST, Byrska-Bishop M, Tober JM, Yao Y, Vandorn D, Opalinska JB, Mills JA, Choi JK, Speck NA, Gadue P, Hardison RC, Nemiroff RL, French DL, et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012; 109:17573-17578.
45. Kusters MA, Verstegen RH, de Vries E. Down syndrome: is it really characterized by precocious immunosenescence? Aging Dis. 2011; 2:538-545.
46. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle Georget Tex. 2010; 9:3151-3156.
47. Blagosklonny MV. TOR-driven aging: speeding car without brakes. Cell Cycle Georget Tex. 2009; 8:4055-4059.
48. Iyer AM, van Scheppingen J, Milenkovic I, Anink JJ, Adle-Biassette H, Kovacs GG, Aronica E. mTOR Hyperactivation in down syndrome hippocampus appears early during development. J Neuropathol Exp Neurol. 2014; 73:671-683.
49. Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Di Domenico F. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta. 2014; 1842:1144-1153.
50. Troca-Marín JA, Alves-Sampaio A, Montesinos ML. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. J Neurosci Off J Soc Neurosci. 2011; 31:9445-9455.
51. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011; 164:9-16.
52. Rakyan VK, Hildmann T, Novik KL, Lewin J, Tost J, Cox AV, Andrews TD, Howe KL, Otto T, Olek A, Fischer J, Gut IG, Berlin K, et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol. 2004; 2:e405.
53. Neri G, Opitz JM. Down syndrome: comments and reflections on the 50th anniversary of Lejeune's discovery. Am J Med Genet A. 2009; 149A:2647-2654.
54. Delabar JM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, Noel B, Sinet PM. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet EJHG. 1993; 1:114-124.
55. Olson LE, Richtsmeier JT, Leszl J, Reeves RH. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science. 2004; 306:687-690.
56. Vacano GN, Duval N, Patterson D. The use of mouse models for understanding the biology of down syndrome and aging. Curr Gerontol Geriatr Res. 2012; 2012:717315.
57. Korbel JO, Tirosh-Wagner T, Urban AE, Chen X-N, Kasowski M, Dai L, Grubert F, Erdman C, Gao MC, Lange K, Sobel EM, Barlow GM, Aylsworth AS, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A. 2009; 106:12031-12036.
58. Lyle R, Béna F, Gagos S, Gehrig C, Lopez G, Schinzel A, Lespinasse J, Bottani A, Dahoun S, Taine L, Doco-Fenzy M, Cornillet-Lefèbvre P, Pelet A, et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet EJHG. 2009; 17:454-466.
59. Huidobro C, Fernandez AF, Fraga MF. The role of genetics in the establishment and maintenance of the epigenome. Cell Mol Life Sci CMLS. 2013; 70:1543-1573.
60. Gowher H, Liebert K, Hermann A, Xu G, Jeltsch A. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. J Biol Chem. 2005; 280:13341-13348.
61. Garagnani P, Bacalini MG, Pirazzini C, Gori D, Giuliani C, Mari D, Di Blasio AM, Gentilini D, Vitale G, Collino S, Rezzi S, Castellani G, Capri M, et al. Methylation of ELOVL2 gene as a new epigenetic marker of age. Aging Cell. 2012; 11:1132-1134.
62. Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB, Johnson CS, Smiraglia DJ, Liu S. IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinforma Oxf Engl. 2012 [cited 2012 August 3]; 28:729-730.
63. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009; 10:48.
64. Francesconi M, Remondini D, Neretti N, Sedivy JM, Cooper LN, Verondini E, Milanesi L, Castellani G. Reconstructing networks of pathways via significance analysis of their intersections. BMC Bioinformatics. 2008; 9 Suppl 4:S9.